Document Detail


Antihypertensive efficacy and tolerability of once daily losartan potassium compared with captopril in patients with mild to moderate essential hypertension.
MedLine Citation:
PMID:  18800454     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: Losartan potassium, an orally active, highly selective AT1 angiotensin II receptor inhibitor, effectively reduces blood pressure by direct receptor blockade, thereby lessening the likelihood of angiotensin converting enzyme (ACE) inhibitor-associated side effects such as dry cough or possibly angioedema. STUDY DESIGN: In this multinational, double-blind, randomized, parallel study, the efficacy and tolerability of once-daily losartan (50 mg) versus once-daily ACE inhibitor (captopril; 50 mg) was evaluated in 163 patients with mild to moderate hypertension. Non-responders after a 6-week treatment period had the dosage doubled for both study drugs until the end of study (week 12). RESULTS: Mean reductions in trough sitting diastolic blood pressure were significantly greater in the losartan group at week 6 (7.8 mmHg) and week 12 (9.1 mmHg) than in the captopril group (5.2 and 5.7 mmHg, respectively). Losartan and captopril were well tolerated. Headache was the most common adverse event reported in both groups. CONCLUSIONS: It was concluded that a once-daily administration of losartan was significantly more effective in this study in lowering sitting diastolic blood pressure than once-daily administration of captopril in patients with mild to moderate essential hypertension. Both losartan and captopril regimes were well tolerated.
Authors:
J M Mallion; D C Bradstreet; L Makris; A I Goldberg; S Halasz; C S Sweet; N Y Lim; O Madonna
Related Documents :
12420044 - Human coagulation factor xii-related "new pressor protein": role of pacap in its cardio...
9683914 - Reciprocal regulation of pulmonary and cardiac angiotensin-converting enzyme in rats wi...
6282024 - Fluctuations in the plasma angiotensin i converting enzyme activity during long-term tr...
17984484 - Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitor...
3510424 - Mechanical ventilation. physiology, equipment design, and management.
9201054 - Effects of intra-aortic balloon occlusion on hemodynamics during, and survival after ca...
Publication Detail:
Type:  Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial    
Journal Detail:
Title:  Journal of hypertension. Supplement : official journal of the International Society of Hypertension     Volume:  13     ISSN:  0952-1178     ISO Abbreviation:  J Hypertens Suppl     Publication Date:  1995 Jul 
Date Detail:
Created Date:  2008-09-19     Completed Date:  2008-10-10     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8501422     Medline TA:  J Hypertens Suppl     Country:  England    
Other Details:
Languages:  eng     Pagination:  S35-41     Citation Subset:  IM    
Affiliation:
Merck Research Laboratories, West Point, PA 19486, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiotensin II Type 1 Receptor Blockers / adverse effects,  pharmacology,  therapeutic use*
Angiotensin-Converting Enzyme Inhibitors / adverse effects,  pharmacology,  therapeutic use*
Blood Pressure / drug effects
Captopril / adverse effects,  pharmacology,  therapeutic use*
Dose-Response Relationship, Drug
Double-Blind Method
Female
Headache / chemically induced
Humans
Hypertension / drug therapy*,  physiopathology
Losartan / adverse effects,  pharmacology,  therapeutic use*
Male
Middle Aged
Chemical
Reg. No./Substance:
0/Angiotensin II Type 1 Receptor Blockers; 0/Angiotensin-Converting Enzyme Inhibitors; 114798-26-4/Losartan; 62571-86-2/Captopril

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Losartan potassium lowers blood pressure measured by ambulatory blood pressure monitoring.
Next Document:  Losartan with hydrochlorothiazide in the treatment of hypertension.